<7776> Cell Seed 566 +24

Continuing rise. Trading has become active in response to the Tokyo Stock Exchange's lifting of temporary measures on margin trading from July 30, and it is still rising today. TSE had enforced regulations that require collateral rates of 50% or more (including cash of 20% or more) for new sales and purchases through margin trading. Japan Securities Finance has also lifted its additional collateral collection measures.

<4883> Modaris 134 -9

Significantly lower. On August 2nd, Mr. Nureki submitted a change report (5% rule report) to the Ministry of Finance at the reception desk. According to the report, Mr. Nureki's shareholding ratio of Modaris' shares decreased from 6.13% to 5.11%. The reporting obligation occurred on July 30th.

<3623> BS 1620 +94

Reverse high, reaching a new high for the year. Although there is no particularly recent material, it is also significantly high against the market today. Since the announcement of the joint examination of settlement management functions and business operations on the metaverse with START LANDS Inc. on June 25, there has been a strong upward trend. The two companies are considering jointly managing settlement functions and business operations on the metaverse that enable efficient handling of settlement-related businesses such as payment methods that are safe, simple, and convenient for various transactions on the metaverse, and fund management operations that correspond to them.

<9560> Progrit 1087 +15

Bounce. After the end of trading on the first day, it has been announced that the enrollment price of the English coaching service "Proglet" will be revised, which is considered good news. The price revision date is September 1, and the enrollment price is for beginners in business English TOEIC L&R, which has been increased from 435,600 yen for 2 months to 457,600 yen. The fees for services other than English coaching will remain unchanged. The price revision is expected to further improve service quality, expand learning content, and strengthen operations.

<6039> Animal High-Tech Medical 2007 -71

Significant decline. The company announced its performance for the first quarter of the fiscal year 25 days after the end of trading. Sales increased by 31.4% year-over-year to 1.25 billion yen, and operating profit increased by 296.0% year-over-year to 0.149 billion yen, but sellers are currently prevailing due to unfavorable market conditions. The number of cases increased significantly, thanks to the recruitment of veterinarians progressing smoothly at existing hospitals and the improvement of the ability to accept medical care. The number of inspections for the image diagnosis service, and the number of rentals and sales of health management equipment rental and sales services all increased compared to the same period of the previous year due to strengthened sales activities and continued measures to strengthen relationships.

<4582> Shinbio Pharmaceuticals 247 -23

It fell sharply. After the end of the first day's trading, they announced their financial estimates for the second quarter of the fiscal year 24, December, which caused selling. Operating loss was 1.719 billion yen (compared to an operating loss of 0.049 billion yen in the same period last year), and ordinary loss was 1.481 billion yen (compared to ordinary profit of 0.066 billion yen in the same period last year), and the deficit expanded. While the erosion of latecomer products is progressing little by little, there is a situation in which prescription was restrained due to concerns about the possibility of infection progression or aggravation after or during Bendamustine treatment, but the situation has been gradually alleviating, and it is proceeding as planned according to the revised financial estimates.